secondary endpoints

Dr Reddy’s Revealed More About 2-DG, and Its Approval Is More Confusing Now

India’s Drug Regulator Has Approved DRDO’s New COVID Drug on Missing Evidence

Is Favipiravir Good for COVID-19? Clinical Trial Says No, Press Release Says Yes

Itolizumab for COVID-19: Who Benefits When the Drug Regulator Is Opaque?